Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

In preparation for health authority interactions in pursuit of marketing approvals in Europe PRINCETON, N.J., Sept. 30, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...

Read More